Abstracts tagged "outcomes and population studies"

Abstract Number: 1849 • 2018 ACR/ARHP Annual Meeting
Remission Status after 18 Years of Follow-up in the Population-Based Nordic Juvenile Idiopathic Arthritis (JIA) Cohort
Mia Glerup¹, Veronika Rypdal^2,3, Ellen Dalen Arnstad^4,5, Maria Ekelund^6,7, Suvi Peltoniemi⁸, Kristiina Aalto⁸, Marite Rygg^9,10, Peter Toftedal¹¹, Susan Nielsen¹¹, Anders Fasth¹², Lillemor Berntson¹³, Ellen Nordal^14,15 and Troels Herlin¹⁶, ¹Department of Pediatrics, Dept. of Pediatrics, Aarhus University Hospital, Denmark, Aarhus, Denmark, ²Dept. of Clin. Med, UIT The Arctic University of Norway, Tromsø, Norway, ³Dept. of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ⁴Dept. Clin. and Mol. Med., NTNU, Norway, Trondheim, Norway, ⁵Dept. of Pediatrics, Levanger Hospital, Nord-Trøndelag, Norway, Trondheim, Norway, ⁶Department of Pediatrics, Dept. of Pediatrics, Ryhov County Hospital, Jonkoping, Sweden, Jonkoping, Sweden, ⁷Uppsala University, Uppsala, Sweden, Jonkobing, Sweden, ⁸Hospital for Children and Adolescents, University of Helsinki, Finland, Helsinki, Finland, ⁹Dep. Clin. and Mol. Med., Dept. Clin. and Mol. Med., NTNU, Norway, Trondheim, Norway, ¹⁰Department of Pediatrics, Dept. of Pediatrics, St. Olavs Hospital, Norway, Trondheim, Norway, ¹¹Department of Pediatrics, Dept. of Pediatrics, Copenhagen University Hospital, Denmark, Copenhagen, Denmark, ¹²Sahlgrenska Academy, University of Gothenburg, Sweden, Gothenburg, Sweden, ¹³Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ¹⁴Departments of Pediatrics, Dept. of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ¹⁵Department of Clinical Medicine, Dept. of Clin. Med, UIT The Arctic University of Norway, Tromsø, Norway, ¹⁶Dept. of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark
Background/Purpose: Innovative changes towards targeted treatment have improved the outcome dramatically for juvenile idiopathic arthritis (JIA) but the question remains how well these patients perform…
Abstract Number: 1180 • 2016 ACR/ARHP Annual Meeting
Class V Lupus Nephritis Results in Significant Numbers of End Stage Renal Disease and Death in a Population-Based Registry
Jennifer Brandt¹, Cristina Drenkard², Jason Cobb³, Gaobin Bao⁴ and S. Sam Lim⁴, ¹Department of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Department of Nephrology, Emory University School of Medicine, Atlanta, GA, ⁴Medicine, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Although the diagnosis of pure class V lupus nephritis (LN) is generally thought to portend a favorable prognosis, outcomes on a population-level are not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].